title: Initiation of PCSK9 inhibition in patients with heterozygous familial hypercholesterolaemia entering adulthood: a new design for living with a high-risk condition?
authors: Mehiläinen Airport Health Center, Lentäjäntie 1 E, Vantaa 00150, Finland alpo.vuorio@gmail.com.
authors: Alpo
authors: A
authors: Vuorio
authors: Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia.
authors: Gerald F
authors: GF
authors: Watts
authors: Wihuri Research Institute, Helsinki, Finland.
authors: Petri T
authors: PT
authors: Kovanen
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002648:Child; D008078:Cholesterol, LDL / Q000378:metabolism; D003327:Coronary Disease / Q000235:genetics; D005260:Female; D006579:Heterozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000235:genetics; D000091362:PCSK9 Inhibitors; D012307:Risk Factors; D017678:Sex Distribution; D055815:Young Adult; D000071449:Proprotein Convertase 9
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9